Every 8-K that CeriBell, Inc. (CBLL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CBLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBLL filings page.
Ceribell, Inc. reported strong top-line growth for the quarter ended June 30, 2026. Total revenue was $28.1 million, up 33% from $21.2 million a year earlier, driven by new account additions and higher utilization across its installed base. Product revenue reached $21.2 million and subscription revenue $6.9 million, both rising about 30% year over year. The company ended the quarter with 712 active accounts.
Profitability remains negative but margins are high. Gross profit was $25.9 million with a 92% gross margin, aided by manufacturing efficiencies, a new Vietnam line, and one-time tariff refunds. Operating expenses increased 37% to $45.9 million as Ceribell invested in commercial expansion, R&D, and legal costs. Net loss widened to $19.3 million, or $0.51 per share, while Adjusted EBITDA loss was $9.8 million.
The balance sheet showed $129.3 million in cash, cash equivalents, and marketable securities at June 30, 2026. Ceribell subsequently entered a new credit facility providing access to up to $60 million in committed capital. The company raised its 2026 revenue outlook to $114–$117 million, implying about 28–31% growth. It also highlighted multiple FDA 510(k) clearances and a CMS New Technology Add-On Payment for its delirium monitoring solution, effective October 1, 2026.
CeriBell, Inc. adjusted its board structure effective July 28, 2026. To achieve a more balanced membership among director classes, the board accepted the resignations of William W. Burke and Joseph M. Taylor as Class I directors and immediately re-elected them as Class II and Class III directors, respectively, with their service otherwise deemed uninterrupted.
On the same date, the authorized board size increased from seven to nine directors, and Sharon L. O’Keefe and Thomas A. West were elected as Class I directors. O’Keefe joined the Compensation Committee and West joined the Audit Committee. Each new non-employee director will receive annual cash compensation and restricted stock units under the company’s Non-Employee Director Compensation Program, plus an initial restricted stock unit award based on dividing $300,000 by the average closing price over the most recent 30 trading days, vesting in three equal annual installments. The company will also enter into standard indemnification agreements with both, and there are no related-party arrangements or interests requiring disclosure.
CeriBell, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 2, 2026. Stockholders elected two Class II directors, Josef Parvizi, M.D., Ph.D., and Rebecca Robertson, to serve until the 2029 annual meeting and until successors are elected.
Parvizi received 25,961,193 votes for and 2,311,420 withheld, while Robertson received 25,948,634 votes for and 2,323,979 withheld; each had 4,374,728 broker non-votes. Stockholders also approved ratifying PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2026 with 32,623,328 votes for, 5,177 against, and 18,836 abstentions.
Ceribell, Inc. reported strong first quarter 2026 growth but wider losses. Total revenue was $26.5 million, up 29% from $20.5 million a year earlier, driven by both product and subscription growth, and gross margin remained high at 87%. The company ended the quarter with 680 active accounts and launched neonate and pediatric products after a successful pilot. Net loss widened to $19.7 million, or $0.52 per share, compared with a $12.8 million loss, as operating expenses rose to $43.9 million on commercial investments, added headcount, and IP litigation costs. Adjusted EBITDA loss was $11.2 million. Ceribell held $141.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026, and raised its 2026 revenue guidance to $112–$116 million, implying approximately 26%–30% growth over the prior year.
Ceribell, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining loss-making. Fourth quarter revenue rose 34% to $24.8 million, with product revenue up 33% and subscription revenue up 37%. Gross margin was a high 87%, but operating expenses increased 24% to $36.2 million, leading to a net loss of $13.5 million, or $0.36 per share.
For full year 2025, revenue grew 36% to $89.1 million, driven by both product and subscription sales. Gross profit reached $78.3 million with an improved gross margin of 88%, but operating expenses rose 42% to $136.7 million, resulting in a net loss of $53.4 million, or $1.46 per share. Ceribell ended the year with $159.3 million in cash, cash equivalents, and marketable securities and 647 active accounts.
The company highlighted multiple regulatory milestones, including two FDA 510(k) clearances and an FDA Breakthrough Device Designation, and guided 2026 revenue to $111–115 million, implying about 25–29% growth over 2025.
Ceribell, Inc. has extended the terms of two office leases in Sunnyvale, California. The 625 Lease covers approximately 11,607 square feet at 625 N. Pastoria Ave., with the term now running through January 31, 2028 and monthly rent of $34,821.00.
The 360 Lease covers approximately 15,600 square feet at 360 N. Pastoria Ave., also extended through January 31, 2028 with monthly rent of $74,147.00. These amendments secure continued access to Ceribell’s existing office and operational space under updated rental terms.
Ceribell, Inc. reported that the U.S. Food and Drug Administration granted 510(k) clearance for its Clarity® algorithm to detect electrographic seizures in newborns, preterm and older. This clearance allows Ceribell to market the Clarity algorithm for this specific clinical use in neonatal patients. The company disclosed the news through a press release, which is attached as an exhibit to this current report.
Ceribell, Inc. (CBLL) furnished an update on its latest performance, announcing that it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company stated that the information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Exchange Act, nor incorporated by reference under the Securities Act unless specifically referenced.
Ceribell, Inc. reports updates to its long-term supply relationship with Shenzhen Everwin Precision Technology. The existing Corporate Supply Agreement, originally signed in January 2022, covers supply of Ceribell’s small and large headbands and licenses product materials needed to manufacture and support these products.
Amendment No. 1 extended the initial two-year term to January 9, 2025, and Amendment No. 2 further extended the term to December 31, 2027 while designating Everwin Precision Holding (Hong Kong) Company Limited as agent and providing for deliveries from a facility in Tijuana, Mexico. On September 22, 2025, Amendment No. 3 added Everwin Precision (Viet Nam) Technology as an additional agent of Everwin China to enable deliveries of headbands from a facility in Vietnam.
Ceribell, Inc. reported that, effective September 17, 2025, its Board of Directors elected Erica Rogers to serve as a director until the next annual meeting of stockholders and until a successor is duly elected and qualified, or her earlier resignation or removal.
She has also been appointed to the Board’s Compensation Committee. As a non-employee director, Ms. Rogers will receive annual cash compensation and restricted stock units under Ceribell’s Non-Employee Director Compensation Program, and the company will enter into its standard-form indemnification agreement with her. The company states there is no arrangement or understanding with any other person regarding her election and that she is not involved in related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.